High glycolic poly (DL lactic co glycolic acid) nanoparticles for controlled release of meropenem

Biomedicine and Pharmacotherapy

Volumn 67, Issue 5, 2013, Pages 431-436

  Nandakumar, Venkatesan ^a   Geetha, Venkatachalam ^a   Chittaranjan, Samuel ^b   Doble, Mukesh ^a  

^a INDIAN INSTITUTE OF TECHNOLOGY MADRAS   (India)

^b CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

Biocompatibility; High glycolic acid; Meropenem; Nanoparticles; Osteomyelitis; PLA; PLGA; Zeta potential

Indexed keywords

MEROPENEM; POLYGLACTIN; POLYLACTIC ACID;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BIOCOMPATIBILITY; CELL VIABILITY; CONTROLLED RELEASE FORMULATION; DRUG STABILITY; ESCHERICHIA COLI; IN VITRO STUDY; MATHEMATICAL MODEL; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE; THERMOSTABILITY; ZETA POTENTIAL;

3T3 CELLS; ANIMALS; ANTI-BACTERIAL AGENTS; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; ESCHERICHIA COLI; LACTIC ACID; MICE; MODELS, THEORETICAL; NANOPARTICLES; POLYGLYCOLIC ACID; POLYMERS; THIENAMYCINS; TIME FACTORS;

EID: 84878350329     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2013.02.004     Document Type: Article

References (33)

1. Nandakumar V., Samuel C., Kurian V.M., Doble M. Characteristics of bacterial biofilm associated with implant material in clinical practice. Polym J 2013, 45:137-152. 10.1038/pj.2012.130.
2. Hickok N.J., Shapiro I.M. Immobilized antibiotics to prevent orthopedic implant infections. Adv Drug Deliv Rev 2012, 64:1165-1176.
3. Pioletti D.P., Gauthier O., Stadelmann V.A., Bujoli B., Guicheux J., Zambelli P.Y., et al. Orthopedic implant used as drug delivery system: clinical situation and state of the research. Curr Drug Deliv 2008, 5:59-63.
4. Nelson C.L., Hickmon S.G., Harrison B.H. Elution characteristics of gentamicin-PMMA beads after implantation in humans. Orthopedics 1994, 17:415.
5. Kendall R.W., Duncan C.P., Smith J.A., Ngui-Yen J.H. Persistence of bacteria on antibiotic loaded acrylic depots: a reason for caution. Clin Orthop Relat Res 1996, 329:273.
6. Klemm K.W. Antibiotic bead chains. Clin Orthop Relat Res 1993, 295:63-76.
7. Kirkpatrick D., Trachtenberg L., Mangino P., Von Fraunhofer J., Seligson D. In vitro characteristics of tobramycin-PMMA beads: compressive strength and leaching. Orthopedics 1985, 8:1130.
8. Patel B., Gupta V., Ahsan F. PEG-PLGA based large porous particles for pulmonary delivery of a highly soluble drug, low molecular weight heparin. J Control Release 2012, 162:310-320.
9. Dailey L.A., Wittmar M., Kissel T. The role of branched polyesters and their modifications in the development of modern drug delivery vehicles. J Control Release 2005, 101:137-149.
10. Na X.M., Gao F., Zhang L.Y., Su Z.G., Ma G.H. Biodegradable microcapsules prepared by self-healing of porous microspheres. ACS Macro Lett 2012, 1:697-700.
11. Abdollahi S., Lotfipour F. PLGA- and PLA-based polymeric nanoparticles for antimicrobial drug delivery. Biomed Intl 2012, 3:1.
12. Fredenberg S., Wahlgren M., Reslow M., Axelsson A. The mechanisms of drug release in poly (lactic-co-glycolic acid)-based drug delivery systems - a review. Int J Pharm 2011, 415:34-52.
13. Govender T., Stolnik S., Garnett M.C., Illum L., Davis S.S. PLGA nanoparticles prepared by nanoprecipitation: drug loading and release studies of a water soluble drug. J Control Release 1999, 57:171-185.
14. Cheng L., Jin C., Lv W., Ding Q., Han X. Developing a highly stable PLGA-mPEG nanoparticle loaded with cisplatin for chemotherapy of ovarian cancer. PloS One 2011, 6:e25433.
15. Danhier F., Ansorena E., Azeitao J., Coco R., Le Breton A., Préat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 2012, 161:505-522.
16. Nandakumar V., Suresh G., Chittaranjan S., Doble M. Synthesis and characterization of hydrophilic high glycolic acid-poly (DL Lactic-Co-Glycolic acid)/polycaprolactam/polyvinyl alcohol blends and its biomedical application as a ureteral material. Ind Eng Chem Res 2012, 52:751-760.
17. Xu Z., Gu W., Huang J., Sui H., Zhou Z., Yang Y., et al. In vitro and in vivo evaluation of actively targetable nanoparticles for paclitaxel delivery. Int J Pharm 2005, 288:361-368.
18. Mendez A.S.L., Steppe M., Schapoval E.E.S. Validation of HPLC and UV spectrophotometric methods for the determination of meropenem in pharmaceutical dosage form. J Pharm Biomed Anal 2003, 33:947-954.
19. Mu L., Feng S.S. A novel controlled release formulation for the anticancer drug. J Control Release 2003, 86:33-48.
20. Cheow W.S., Hadinoto K. Enhancing encapsulation efficiency of highly water-soluble antibiotic in poly (lactic-co-glycolic acid) nanoparticles: modifications of standard nanoparticle preparation methods. Colloids Surf A Physicochem Eng Asp 2010, 370:79-86.
21. Prabhakar P.K., Raj S., Anuradha P., Sawant S.N., Doble M. Biocompatibility studies on polyaniline and polyaniline-silver nanoparticle coated polyurethane composite. Colloids Surf B Biointerfaces 2011, 86:146-153.
22. Chung Y.I., Kim J.C., Kim Y.H., Tae G., Lee S.Y., Kim K., et al. The effect of surface functionalization of PLGA nanoparticles by heparin-or chitosan-conjugated Pluronic on tumor targeting. J Control Release 2010, 143:374-382.
23. Ribble D., Goldstein N.B., Norris D.A., Shellman Y.G. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol 2005, 5:12.
24. Averineni R.K., Shavi G.V., Gurram A.K., Deshpande P.B., Arumugam K., Maliyakkal N., et al. PLGA 50: 50 nanoparticles of paclitaxel: development, in vitro anti-tumor activity in BT-549 cells and in vivo evaluation. Bull Mater Sci 2012, 35:319.
25. Jeffery H., Davis S.S., O'Hagan D.T. The preparation and characterization of poly (lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique. Pharmaceut Res 1993, 10:362-368.
26. Ravi S., Peh K., Darwis Y., Murthy B.K., Singh T.R.R., Mallikarjun C. Development and characterization of polymeric microspheres for controlled release protein loaded drug delivery system. Indian J Pharm Sci 2008, 70:303.
27. Hans M., Lowman A. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002, 6:319-327.
28. Hans M.L., Lowman A.M. Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 2002, 6:319-327.
29. Lao L.L., Peppas N.A., Boey F.Y.C., Venkatraman S.S. Modeling of drug release from bulk-degrading polymers. Int J Pharm 2011, 418:28-41.
30. Makadia H.K., Siegel S.J. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011, 3:1377-1397.
31. Batycky R.P., Hanes J., Langer R., Edwards D.A. A theoretical model of erosion and macromolecular drug release from biodegrading microspheres. J Pharm Sci 1997, 86:1464-1477.
32. Dailey L.A., Jekel N., Fink L., Gessler T., Schmehl T., Wittmar M., et al. Investigation of the proinflammatory potential of biodegradable nanoparticle drug delivery systems in the lung. Toxicol Appl Pharmacol 2006, 215:100-108.
33. Olivier J.C., Fenart L., Chauvet R., Pariat C., Cecchelli R., Couet W. Indirect evidence that drug brain targeting using polysorbate 80-coated polybutylcyanoacrylate nanoparticles is related to toxicity. Pharmaceut Res 1999, 16:1836-1842.